compound-24

>50x family-selective HPK1 kinase inhibitor

tumor clearance w/ PD-1i (oral 100 mpk BID)

from IRAK4 inhibitor and homology modeling

ACS. Med. Chem. Lett., Feb. 19, 2021

Bristol Myers Squibb, Cambridge, MA

6. The Bristol Myers Squibb (BMS) HPK1 kinase inhibitor, “compound 24” is an oral tool compound intended for cancer immunotherapy, with >50x selectivity against family members including GLK. The…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks